Core Viewpoint - Maiwei Biotech (688062.SH) has received registration approval from the Drug Regulatory Authority of Pakistan (DRAP) for its two biosimilar products, 9MW0311 and 9MW0321, marking a significant milestone in the company's global commercialization strategy [1] Group 1: Product Approval - The two biosimilar products, known domestically as Mai Li Shu® and Mai Wei Jian®, are the first biosimilars of de-sumumab approved by the DRAP [1] - This approval represents the company's first overseas registration for its products, enhancing its competitive edge in the global market [1] Group 2: Market Potential - Pakistan, with a population of 240 million, is identified as a key emerging market with growing pharmaceutical demand, aligning with the company's strategic focus on expanding in such regions [1] - The approval is expected to positively impact the company's efforts to expand into new markets and improve its core competitiveness [1] Group 3: Global Strategy - As of the announcement date, the company has signed formal cooperation agreements covering dozens of countries in overseas markets [1] - The company aims to continue promoting the commercialization of its products in more countries, further enhancing the global accessibility of its de-sumumab injection [1]

Core Viewpoint - Maiwei Biotech (688062) has received regulatory approval for two biosimilar products in Pakistan, marking a significant milestone for the company and the biosimilar market in the region [1] Group 1: Regulatory Approvals - The Searle Company Limited has notified Maiwei Biotech that its two biosimilar injections, 9MW0311 and 9MW0321, have been approved by the Pakistan Drug Regulatory Authority [1] - This approval represents the first registration of a biosimilar drug for de-sulfanil in Pakistan [1] - The products are marketed under the names Mai Li Shu and Mai Wei Jian in China [1] Group 2: Clinical Trials - Maiwei Biotech has also received an acceptance notice from the National Medical Products Administration for the Phase II clinical trial application of 9MW3811 injection, which is intended for the treatment of pathological scars [1]

Core Viewpoint - The company has received regulatory approval for two biosimilar products in Pakistan, marking a significant milestone in its international expansion efforts [1] Group 1: Product Approval - The Searle Company Limited has notified the company that its two biosimilar injections, 9MW0311 and 9MW0321, have been approved by the Drug Regulatory Authority of Pakistan (DRAP) [1] - This approval represents the first registration of a biosimilar drug for denosumab by the DRAP [1] - The products are the company's first to receive overseas registration, indicating a successful entry into the international market [1] Group 2: Product Details - 9MW0311, marketed as "迈利舒" in China, is indicated for osteoporosis in postmenopausal women at high risk of fractures [1] - 9MW0321, marketed as "迈卫健" in China, is used for the treatment of giant cell tumor of bone (GCTB) that cannot be surgically removed or where surgery may lead to severe functional impairment [1]